TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3069520
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg anhydrous theophylline administered orally every 12 h for 7 days
Study: 3069520
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg anhydrous theophylline
Study: 3069520
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg choline theophyllinate
Study: 25824436
Drug: Esophageal-directed hypnotherapy
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esophageal-directed hypnotherapy (EHYP) - 7 weekly sessions
Study: 19889113
Drug: Pre-emptive fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-emptive fentanyl 25 microg (0.5 ml) 1 min before administration of fentanyl 125 microg
Study: 19889113
Drug: Pre-emptive fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-emptive fentanyl 25 microg (0.5 ml) 1 min before administration of fentanyl 150 microg
Study: 19889113
Drug: Saline 0.9%
Normalized name: CVS Saline 0.9% Nasal Mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 0.9% (0.5 ml) 1 min before administration of fentanyl 150 microg
Study: 19034284
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiotherapy for colorectal cancer
Study: 13129460
Drug: Coconut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut flour (200-250 g/kg) in macaroons
Study: 13129460
Drug: Coconut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut flour (200-250 g/kg) in carrot cake
Study: 13129460
Drug: Coconut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut flour (150 g/kg) in test foods
Study: 13129460
Drug: Coconut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut flour (50 g/kg) in pan de sal
Study: 13129460
Drug: Coconut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut flour (100 g/kg) in multigrain loaf
Study: 13129460
Drug: Coconut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut flour (50 g/kg) in granola bar
Study: 13129460
Drug: Coconut flour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut flour (100 g/kg) in cinnamon bread
Study: 6100497
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose methotrexate regime (three cycles of etoposide, adriamycin and methotrexate at conventional dosage)
Study: 6100497
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose methotrexate regime (three cycles of etoposide and adriamycin with five courses of high dose methotrexate and folinic acid rescue)
Study: 6100497
Drug: Alternative four
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative four drug regime (procarbazine, vincristine, cyclophosphamide and CCNU)
Study: 31161374
Drug: Supportive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive and symptomatic treatments (group B)
Study: 22274684
Drug: Lansoprazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (15 mg/d if <30 kg; 30 mg/d if ≥30 kg)
Study: 12228773
Drug: Carvedilol administered
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carvedilol administered twice daily for 8 months
Study: 322671
Drug: Chlordesmethyldiazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlordesmethyldiazepam (2 mg orally) administered for 7 consecutive evenings
Study: 21688560
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase Inhibitors (AIN's)
Study: 9119980
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone 1000 mg daily for 3 days
Study: 9119980
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone 48 mg daily for one week, 24 mg daily for one week, and 12 mg daily for one week
Study: 9119980
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone regimen
Study: 8222034
Drug: Sitting position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitting position with 2.0 ml hyperbaric bupivacaine 0.5%
Study: 8222034
Drug: Left lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left lateral position with 2.0 ml hyperbaric bupivacaine 0.5%
Study: 3531044
Drug: Dapsone (DDS)
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone (DDS) approximately 2 mg per kilogram body weight per day for 21 days
Study: 3531044
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving the drug)
Study: 25490803
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of self-leveling carousel and adjustable cart
Study: 12047603
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg triazolam (TL)
Study: 12047603
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg triazolam (TH)
Study: 12047603
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg brotizolam (BR)
Study: 2265259
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen (TM), 30 mg per day for 2 years
Study: 31426760
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) with doses of 20 Gy in 1 fraction, 30 Gy in 3 fractions, or 35 Gy in 5 fractions, completed within 2 weeks.
Study: 31426760
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care palliative-intent treatments (Control group).
Study: 25862428
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L of polyethylene glycol plus bisacodyl (n = 31)
Study: 24219197
Drug: Low-intensity nonprogressive
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity nonprogressive resistance training (L-RT)
Study: 17276533
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) to the left breast
Study: 8975918
Drug: 23-valent polysaccharide
Normalized name: pneumococcal 23-valent polysaccharide vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23-valent polysaccharide vaccine (PS) (25 micrograms of polysaccharide per serotype)
Study: 7932517
Drug: Pravastatin 10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10-40 mg once daily
Study: 25422235
Drug: Chongcao Yigan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chongcao Yigan Capsule
Study: 19884368
Drug: Nemonoxacin 25
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 25 mg
Study: 19884368
Drug: Nemonoxacin 50
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 50 mg
Study: 19884368
Drug: Nemonoxacin 1000
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 1000 mg
Study: 19884368
Drug: Nemonoxacin 1500
Normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemonoxacin 1500 mg
Study: 12094846
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg and 20 mg
Study: 7724891
Drug: Morphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2.5 mg i.v. on‐demand (Group 1)
Study: 7724891
Drug: Clonixin 400
Normalized name: clonixin
DrugBank: Clonixin (DB09218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonixin 400 mg/day i.v. infusion (Group 2)
Study: 7724891
Drug: Morphine 0.4
Normalized name: morphine 0.4 mg/mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 0.4 mg/kg/day i.v. infusion (Group 3)
Study: 7724891
Drug: Clonixin 400
Normalized name: clonixin
DrugBank: Clonixin (DB09218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonixin 400 mg/day plus morphine 0.4 mg/kg/day i.v. infusion (Group 4)
Study: 6772386
Drug: Diltiazem, 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem, 240 mg daily dose
Study: 27530339
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of autologous bone marrow cells (BMCs) by local intramuscular application (n=32)
Study: 27530339
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml of autologous bone marrow cells (BMCs) by intra-arterial application (n=30)
Study: 24383962
Drug: amikacin/fosfomycin (300/120
Approvals — FDA: no, EMA: no, PMDA: no
Description: amikacin/fosfomycin (300/120 mg combination)
Study: 15447697
Drug: Riboflavin 400
Normalized name: riboflavin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin 400 mg, Magnesium 300 mg, Feverfew 100 mg
Study: 15447697
Drug: Placebo (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (25 mg riboflavin)
Study: 11240597
Drug: IM Fosphenytoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM Fosphenytoin (10 mg/kg)
Study: 11240597
Drug: IM Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM Saline (up to 19.5 mL or 2 mL)
Study: 9855446
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of influenza vaccine
Study: 9855446
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of influenza vaccine (1994-1995 season)
Study: 7863247
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily a.m.)
Study: 7863247
Drug: Nizatidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine (300 mg twice daily)
Study: 28961465
Drug: Pembrolizumab (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (both doses)
Study: 17700646
Drug: E2 (1
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 (1 mg/day for 1 month, then 2 mg/day for 2 months)
Study: 16484769
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mug once daily
Study: 10697374
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid composition (100 mg 3 times a day sublingually)
Study: 10697374
Drug: Preductal (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preductal (20 mg 3 times a day)
Study: 31291793
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg lipoic acid (LA) once daily for 12 weeks
Study: 16082837
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy including solutions of colloids and crystalloids (n=43)
Study: 12584787
Drug: Folium Ginkgo
Normalized name: Ginkgo folium
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folium Ginkgo extract (FGE) 15 mg/kg.d for 7-8 days
Study: 10721681
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 to 30 mg per day)
Study: 10721681
Drug: Citalopram (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (10 to 15 mg per day)
Study: 10721681
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 to 60 mg per day)
Study: 10721681
Drug: Clomipramine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (60 to 90 mg per day)
Study: 1493669
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 mg three times/day)
Study: 4014126
Drug: Stepped Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped Care (intensive treatment group)
Study: 10552979
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg), Amoxycillin (1 g), Metronidazole (400 mg) bd for 7 days (OAM)
Study: 10552979
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg), Clarithromycin (250 mg), Metronidazole (400 mg) bd for 7 days (OCM)
Study: 29310119
Drug: Amoxicillin 250
Normalized name: amoxicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 250 mg b.i.d. (group B; experimental)
Study: 29310119
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg b.i.d. (group A; conventional)
Study: 23342765
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO2) combined with drugs
Study: 16286100
Drug: Hydration and
Normalized name: Blistex Enhancement Series (Ultra-Rich Hydration and Lip Vibrance) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration and tenoxicam (20 mg orally once daily)
Study: 2228650
Drug: 10 units
Normalized name: Omnipod GO 10 Units/Day Pods
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 units of heparin in 1 ml sodium chloride solution
Study: 30948522
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of levobupivacaine [0.125%] bolus delivered every 2 hours (n=20)
Study: 30948522
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of levobupivacaine [0.125%] (6 mL/hour) (n=20)
Study: 30948522
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of levobupivacaine [0.125%]
Study: 30948522
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of levobupivacaine [0.125%]
Study: 26386766
Drug: RenalGuard group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RenalGuard group (hydration with normal saline solution controlled by the RenalGuard system and furosemide)
Study: 26386766
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal saline solution)
Study: 21315352
Drug: Metoprolol CR/XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol CR/XL (25mg once daily)
Study: 15567796
Drug: Ropivacaine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 20 ml (group R, n=33)
Study: 11046100
Drug: HOE 140
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HOE 140 (bradykinin B(2) receptor antagonist)
Study: 11046100
Drug: Furosemide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (0.5 mg/kg i.v.)
Study: 8407392
Drug: Hyperfractionated radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiotherapy at 75.6 Gy (1.26 Gy twice daily for 6 weeks)
Study: 2944668
Drug: Constant SC
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant SC infusion of ICI 118630
Study: 2944668
Drug: Monthly SC
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly SC slow-release depot formulation of ICI 118630
Study: 31128948
Drug: Interval cytoreductive
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin
Study: 31128948
Drug: Interval cytoreductive
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval cytoreductive surgery without hyperthermic intraperitoneal chemotherapy (HIPEC)
Study: 18379802
Drug: Bio-resorbable implant
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bio-resorbable implant (Reunite osteosynthesis plate by Biomet Inc)
Study: 18379802
Drug: Metal implant
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal implant
Study: 18379802
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (bio-resorbable and metal implants)
Study: 10189654
Drug: Intramuscular morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular morphine sulphate (0.15 mg.kg‐1)
Study: 10189654
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (1.5 mg.kg‐1)
Study: 31584939
Drug: Maternal nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal nutrition intervention (nutrition counseling and micronutrient supplements)
Study: 23384077
Drug: Lower alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lower alcohol dose group (mean BAC 0.04%, N = 40)
Study: 23384077
Drug: Higher alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher alcohol dose group (mean BAC 0.06%, N = 44)
Study: 18056792
Drug: 20% Intralipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% Intralipid infusion [0.7 ml.kg(‐1).h(‐1) (1.54 g/kg)] for 11 h
Study: 18056792
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline infusion for 11 h (control)
Study: 12195603
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 micro g once daily
Study: 12728159
Drug: Salmeterol 50
Normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol 50 micro g twice daily
Study: 11590493
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (PI plus two nucleosides)
Study: 11590493
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (PI plus one nucleoside)
Study: 9305714
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (8 cycles)
Study: 9305714
Drug: Chemotherapy (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (6 cycles) plus radiation therapy
Study: 8371918
Drug: Apraclonidine 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraclonidine 0.5% (3 times daily)
Study: 8371918
Drug: Apraclonidine 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraclonidine 0.25% (3 times daily)
Study: 29914095
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD) of Ecologic® Barrier (1 × 10^10 CFU per day)
Study: 29914095
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (LD) of Ecologic® Barrier (2.5 × 10^8 CFU per day)
Study: 27893675
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg TUDCA plus UDCA placebo
Study: 27893675
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg UDCA plus TUDCA placebo
Study: 21993405
Drug: Dose response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose response modelling
Study: 20070758
Drug: Single ball-type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ball-type mini-implants (Group I)
Study: 20070758
Drug: Mini-implants splinted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implants splinted with a prefabricated bar (Group II)
Study: 19000365
Drug: MDI (Metered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDI (Metered Dose Inhaler)
Study: 16186088
Drug: Behavioral drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral drug abuse therapies
Study: 10571351
Drug: Laser trabeculoplasty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser trabeculoplasty and topical betaxolol twice daily in eligible eyes
Study: 10571351
Drug: No initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No initial treatment with close follow-up
Study: 9339040
Drug: Scleral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scleral and corneal tunnel incisions (6.0‐mm W; 3.5‐ and 2.5‐mm L scleral tunnel; 4.1‐mm linear and 2.5‐mm L corneal tunnel)
Study: 2643357
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment plus a fixed schedule of nicotine gum
Study: 2643357
Drug: Behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral treatment plus an ad lib schedule
Study: 1259398
Drug: Oxolinic acid
Normalized name: oxolinic acid
DrugBank: Oxolinic acid (DB13627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxolinic acid (1.5 g twice daily by mouth for 5 to 12 days)
Study: 1259398
Drug: Amoxicillin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (3 patients responded to this treatment)
Study: 26100002
Drug: HP gel
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP gel + KTP laser irradiation
Study: 26100002
Drug: HP gel
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP gel + Er:YAG irradiation
Study: 26100002
Drug: HP gel
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP gel without laser irradiation
Study: 23330721
Drug: 14-bp insertion/deletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-bp insertion/deletion polymorphism of HLA-G gene (dominant model)
Study: 23330721
Drug: 14-bp insertion/deletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-bp insertion/deletion polymorphism of HLA-G gene (codominant model)
Study: 23330721
Drug: 14-bp insertion/deletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-bp insertion/deletion polymorphism of HLA-G gene (dominant model after sensitivity analysis)
Study: 23330721
Drug: 14-bp insertion/deletion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-bp insertion/deletion polymorphism of HLA-G gene (codominant model after sensitivity analysis)